Performance of the ESC/ERS 4-strata risk stratification model for pulmonary arterial hypertension with missing variables

Abstract

In patients with PAH, the ESC/ERS 4-strata risk model maintains some of its discriminative power when one of the three parameters (WHO-FC, 6MWD, and BNP/NT-proBNP) is missing, although with an increasing likelihood of overestimating risk https://bit.ly/46mz83d

Conflict of interest statement

Conflict of interest: C. Pausch and D. Huscher have no potential conflicts of interest to disclose. D. Pittrow has received fees for consultations from Actelion, Amgen, Aspen, Bayer, Biogen, Boehringer Ingelheim, Daiichi Sankyo, MSD, Novartis, Sanofi-Genzyme, Takeda, Viatris and Zambon. M.M. Hoeper has received fees for lectures and/or consultations from Acceleron, Actelion, AOP Health, Bayer, Ferrer, GSK, Janssen, MSD and Pfizer.

Figures

FIGURE 1

Kaplan–Meier survival estimates based on four risk strata obtained at first follow-up when a) all parameters (World Health Organization (WHO) functional class (FC), 6-min walk distance (6MWD) and brain natriuretic peptide (BNP)/N-terminal pro-BNP (NT-proBNP)) were available, b) when WHO-FC was missing, c) when 6MWD was missing and d) when BNP/NT-proBNP was missing.